• Special Issue Topic

    Nanomedicine and Cancer Immunotherapy

    Submission Deadline: January 01, 2023

    Guest Editors

    Dr. Haijun Yu E-Mail

    Principal Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    Research Keywords: nanomedicine, immunotherapy, drug delivery, gene therapy, biomedical engineering

    Dr. Yang Shi E-Mail

    Group Leader, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Helmholtz Institute for Biomedical Engineering, Aachen, Germany

    Research Keywords: nanomedicine, immunotherapy, tumor targeting, biomaterials, biomedical engineering

    About the Special Issue

    Immunotherapy has shifted the paradigm of cancer research and management both in laboratory and clinic. Cancer immunotherapy with immune checkpoint inhibitors or small molecular agonists has been employed to initiate systemic and sustainable antitumor immune response for tumor regression and metastasis suppression. However, the therapeutic benefits for cancer immunotherapy are impaired by the moderate response rate and severe immune-related reverse effects. The advances of caner nanomedicine show promising potential for improving cancer immunotherapy by optimizing the pharmacokinetic profiles of immune modulators and co-delivery of multiple therapeutic agents.

    In this special issue of “Nanomedicine and Cancer Immunotherapy”, we welcome both review articles and original research papers to summarize the most recent advances of nanomedicine for cancer vaccination, improved delivery of tumor antigen, delivery of small molecular immune modulators, etc. This special issue should be of high impact improving the understanding and clinical translation of nano-immunotherapy.

    Keywords: nanomedicine, cancer immunotherapy, tumor immune microenvironment, drug delivery, adaptive immune response, innate immune response

    Published Articles

    Open Access
    Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment
    Cancer is the leading cause of mortality worldwide, which necessitates our consideration related to novel treatment approach. Tumor cells at the tumor microenvironment (TME), regulate a plethora of  [...] Read more.
    Priyanka Singh ... Anita Kamra Verma
    Published: February 16, 2022 Explor Med. 2022;3:22–42
    DOI: https://doi.org/10.37349/emed.2022.00072
    Open Access
    Emerging nanomaterials for cancer immunotherapy
    Immunotherapy is a unique approach to treat cancer that targets tumours besides triggering the immune cells. It attempts to harness the supremacy and specificity of immune cells for the regression of malignancy. The key strategy o [...] Read more.
    Sureshbabu Ram Kumar Pandian ... Krishnan Sundar
    Published: June 30, 2021 Explor Med. 2021;2:208–231
    DOI: https://doi.org/10.37349/emed.2021.00043
    Open Access
    AS1411-functionalized delivery nanosystems for targeted cancer therapy
    Nucleolin (NCL) is a multifunctional nucleolar phosphoprotein harboring critical roles in cells such as cell proliferation, survival, and growth. The dysregulation and overexpression of NCL are related to various pathologic and on [...] Read more.
    Pooria Safarzadeh Kozani ... Mohammad Tariq Malik
    Published: April 30, 2021 Explor Med. 2021;2:146–166
    DOI: https://doi.org/10.37349/emed.2021.00039
    Open Access
    Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles
    The limitations of current cancer treatments have stimulated the application of nanotechnology to develop more effective and safer cancer therapies. Remarkable progress has been made in the development of nanomedicine to overcome  [...] Read more.
    Carmen Paus ... Alessandra Cambi
    Published: April 30, 2021 Explor Med. 2021;2:167–185
    DOI: https://doi.org/10.37349/emed.2021.00040
    Open Access
    Cell-derived vesicles for delivery of cancer immunotherapy
    In recent years, cancer immunotherapy has received unprecedented attention due to the clinical achievements. The applications of biomedical engineering and materials science to cancer immunotherapy have solved the challenges cause [...] Read more.
    Jialu Xu, Chao Wang
    Published: February 28, 2021 Explor Med. 2021;2:39–59
    DOI: https://doi.org/10.37349/emed.2021.00031